KR20250004257A - 고형 암을 치료하기 위한 조성물 및 방법 - Google Patents

고형 암을 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20250004257A
KR20250004257A KR1020247037139A KR20247037139A KR20250004257A KR 20250004257 A KR20250004257 A KR 20250004257A KR 1020247037139 A KR1020247037139 A KR 1020247037139A KR 20247037139 A KR20247037139 A KR 20247037139A KR 20250004257 A KR20250004257 A KR 20250004257A
Authority
KR
South Korea
Prior art keywords
cancer
composition
bladder
glycine
myeloperoxidase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247037139A
Other languages
English (en)
Korean (ko)
Inventor
로버트 씨. 알렌
잭슨 티. 스테펜 주니어
Original Assignee
엑스옥세미스 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엑스옥세미스 인코퍼레이티드 filed Critical 엑스옥세미스 인코퍼레이티드
Publication of KR20250004257A publication Critical patent/KR20250004257A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/03—Oxidoreductases acting on the CH-OH group of donors (1.1) with a oxygen as acceptor (1.1.3)
    • C12Y101/03004—Glucose oxidase (1.1.3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/02—Oxidoreductases acting on a peroxide as acceptor (1.11) with H2O2 as acceptor, one oxygen atom of which is incorporated into the product (1.11.2)
    • C12Y111/02002—Myeloperoxidase (1.11.2.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020247037139A 2022-04-13 2023-04-12 고형 암을 치료하기 위한 조성물 및 방법 Pending KR20250004257A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263330553P 2022-04-13 2022-04-13
US63/330,553 2022-04-13
PCT/US2023/018289 WO2023200842A1 (en) 2022-04-13 2023-04-12 Compositions and methods for treating solid cancer

Publications (1)

Publication Number Publication Date
KR20250004257A true KR20250004257A (ko) 2025-01-07

Family

ID=88330172

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247037139A Pending KR20250004257A (ko) 2022-04-13 2023-04-12 고형 암을 치료하기 위한 조성물 및 방법

Country Status (10)

Country Link
US (1) US20250332226A1 (https=)
EP (1) EP4507793A1 (https=)
JP (1) JP2025512366A (https=)
KR (1) KR20250004257A (https=)
CN (1) CN119677528A (https=)
AU (1) AU2023252830A1 (https=)
CA (1) CA3246603A1 (https=)
IL (1) IL316053A (https=)
MX (1) MX2024012316A (https=)
WO (1) WO2023200842A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486408A (en) * 1981-04-07 1984-12-04 Kiel Johnathan L Insoluble crosslinked cytotoxic oxidase-peroxidase system
WO1990003185A1 (en) * 1988-09-28 1990-04-05 Ideon Corporation Combination enzyme immunotherapeutics
WO2007103525A2 (en) * 2006-03-09 2007-09-13 Glanbia Nutritionals (Ireland) Limited Cationic whey protein composition
WO2013009910A2 (en) * 2011-07-11 2013-01-17 Exoxemis, Inc. Eosinophil peroxidase compositions and methods of their use
WO2021202592A2 (en) * 2020-03-30 2021-10-07 Oregon Health & Science University Monoclonal antibodies for intracellular delivery of payloads
CA3196357A1 (en) * 2020-11-11 2022-05-19 Robert C. Allen Compositions and methods for treating solid cancer

Also Published As

Publication number Publication date
EP4507793A1 (en) 2025-02-19
AU2023252830A1 (en) 2024-10-10
IL316053A (en) 2024-11-01
WO2023200842A1 (en) 2023-10-19
CN119677528A (zh) 2025-03-21
MX2024012316A (es) 2024-11-08
US20250332226A1 (en) 2025-10-30
JP2025512366A (ja) 2025-04-17
CA3246603A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
EP1194163B1 (en) Novel methods and medicament for treating infectious diseases involving microbial biofilms
US20100178273A1 (en) Methods and compositions for treating mucositis
JP2010148509A (ja) アルギニンを欠乏させることによってヒト悪性腫瘍を治療する医薬品及び方法
Teicher et al. Transforming growth factor-β in in vivo resistance
CN103764137A (zh) 嗜伊红粒细胞过氧化物酶组合物和它们的使用方法
WO2010023195A2 (en) Compositions and methods for treating cancer
US5552390A (en) Phosphorothioate inhibitors of metastatic breast cancer
Yan et al. Mitigation of radiation‐induced skin injury by AAV2‐mediated MnSOD gene therapy
KR20230106646A (ko) 고형 암을 치료하기 위한 조성물 및 방법
EP3442564B1 (en) Composition of proenzymes for cancer treatment
KR20250004257A (ko) 고형 암을 치료하기 위한 조성물 및 방법
JP3980088B2 (ja) 傷治癒を改善するプラスミノーゲン活性化因子からなる製剤の使用
US6984619B1 (en) Method for protection against tumor metastasis formation
HK40098212A (zh) 用於治疗实体癌的组合物和方法
JP2006505290A (ja) 抗酸化医薬化合物、ポリペプチドの産生方法、治療方法
JPH0653670B2 (ja) 化学療法剤の副作用低減化剤
Gallin Interferon-γ in the treatment of the chronic granulomatous diseases of childhood
WO2009149201A1 (en) Methods of treatment for pulmonary fibrosis
CN100484575C (zh) 一类封闭myc细胞增殖途径的染色质肽药物分子
WO1995020650A1 (en) Strain of trichoderma harzianum rifai, process for obtaining l-lysine-alpha-oxidase as an inhibitor of viral and bacterial activity, immunomodulator and skin healing agent
CN105477627B (zh) 治疗前列腺癌的组合物及其用途
EP3373956B1 (en) Proenzyme composition
JPH03204818A (ja) ヒトａｄｆを含有する医薬組成物
CA2525672A1 (en) Use of peroxovanadium compounds as tumour cell growth suppressor
US12419938B2 (en) Proenzyme composition

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000